FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1970779231> ?p ?o ?g. }

• W1970779231 endingPage "e15" @default.
• W1970779231 startingPage "e7" @default.
• W1970779231 abstract "Most patients with advanced non-small cell lung cancer (NSCLC) require systemic chemotherapy. Vandetanib, targeting epidermal growth factor receptor and vascular endothelial growth factor receptor signalling in NSCLC, has recently been evaluated in combination chemotherapy in advanced NSCLC. However, the advantage of chemotherapy plus vandetanib over chemotherapy alone in advanced NSCLC remains largely unknown. A meta-analysis of randomised controlled trials was carried out to compare the efficacy and toxicity of chemotherapy plus vandetanib with chemotherapy alone in advanced NSCLC.The PubMed database, American Society of Clinical Oncology, European Society for Medical Oncology and the Cochrane Library and references of published trials were searched. Two reviewers independently assessed the quality of the trials. Data were extracted and the overall response rate, pooled progression-free survival, overall survival with 95% confidence intervals and main toxicity were analysed.Four randomised controlled trials involving 2160 patients with advanced NSCLC were ultimately analysed. Compared with chemotherapy alone, chemotherapy plus vandetanib significantly increased the overall response rate (relative risk = 1.96, 95% confidence interval = 1.53--2.52) and progression-free survival (hazard ratio = 0.79, 95% confidence interval = 0.71-0.87), but there was no significant difference in overall survival (hazard ratio = 0.91, 95% confidence interval = 0.79-1.03). Patients who received chemotherapy plus vandetanib had more rash, diarrhoea, hypertension and QTc prolongation (odds ratio = 2.32, 95% confidence interval = 1.93-2.79; odds ratio = 1.64, 95% confidence interval = 1.37-1.97; odds ratio = 4.08, 95% confidence interval = 2.51-6.01, odds ratio = 17.77, 95% confidence interval = 3.54-61.66, respectively), and less nausea and vomiting (odds ratio = 0.70, 95% confidence interval = 0.58-0.85; odds ratio = 0.69, 95% confidence interval = 0.55-0.86, respectively). The incidences of haemorrhage, fatigue and cough were comparable between the two groups.Although similar in overall survival, chemotherapy plus vandetanib showed particular advantages over chemotherapy alone in terms of progression-free survival and overall response rate. The toxicity was comparable between the two groups. Therefore, chemotherapy plus vandetanib might be a safe and valid therapeutic option for advanced NSCLC patients." @default.
• W1970779231 created "2016-06-24" @default.
• W1970779231 creator A5005476467 @default.
• W1970779231 creator A5006631538 @default.
• W1970779231 creator A5014172067 @default.
• W1970779231 creator A5044420311 @default.
• W1970779231 creator A5046198918 @default.
• W1970779231 creator A5046856172 @default.
• W1970779231 creator A5047686585 @default.
• W1970779231 date "2013-01-01" @default.
• W1970779231 modified "2023-09-25" @default.
• W1970779231 title "Chemotherapy plus Vandetanib or Chemotherapy Alone in Advanced Non-small Cell Lung Cancer: A Meta-analysis of Four Randomised Controlled Trials" @default.
• W1970779231 cites W1534608409 @default.
• W1970779231 cites W1839238860 @default.
• W1970779231 cites W1976155116 @default.
• W1970779231 cites W1978111504 @default.
• W1970779231 cites W1986215651 @default.
• W1970779231 cites W2004350020 @default.
• W1970779231 cites W2028299022 @default.
• W1970779231 cites W2060299515 @default.
• W1970779231 cites W2079419271 @default.
• W1970779231 cites W2098943804 @default.
• W1970779231 cites W2100018005 @default.
• W1970779231 cites W2102590541 @default.
• W1970779231 cites W2107666024 @default.
• W1970779231 cites W2115078104 @default.
• W1970779231 cites W2119865588 @default.
• W1970779231 cites W2122553809 @default.
• W1970779231 cites W2125212831 @default.
• W1970779231 cites W2126655764 @default.
• W1970779231 cites W2127809030 @default.
• W1970779231 cites W2130451229 @default.
• W1970779231 cites W2130652363 @default.
• W1970779231 cites W2134667653 @default.
• W1970779231 cites W2138297714 @default.
• W1970779231 cites W2145835533 @default.
• W1970779231 cites W2150335765 @default.
• W1970779231 cites W2157823046 @default.
• W1970779231 cites W2158734599 @default.
• W1970779231 cites W4234236664 @default.
• W1970779231 cites W4235781850 @default.
• W1970779231 doi "https://doi.org/10.1016/j.clon.2012.09.005" @default.
• W1970779231 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23177099" @default.
• W1970779231 hasPublicationYear "2013" @default.
• W1970779231 type Work @default.
• W1970779231 sameAs 1970779231 @default.
• W1970779231 citedByCount "12" @default.
• W1970779231 countsByYear W19707792312013 @default.
• W1970779231 countsByYear W19707792312015 @default.
• W1970779231 countsByYear W19707792312017 @default.
• W1970779231 countsByYear W19707792312019 @default.
• W1970779231 countsByYear W19707792312020 @default.
• W1970779231 countsByYear W19707792312021 @default.
• W1970779231 countsByYear W19707792312022 @default.
• W1970779231 crossrefType "journal-article" @default.
• W1970779231 hasAuthorship W1970779231A5005476467 @default.
• W1970779231 hasAuthorship W1970779231A5006631538 @default.
• W1970779231 hasAuthorship W1970779231A5014172067 @default.
• W1970779231 hasAuthorship W1970779231A5044420311 @default.
• W1970779231 hasAuthorship W1970779231A5046198918 @default.
• W1970779231 hasAuthorship W1970779231A5046856172 @default.
• W1970779231 hasAuthorship W1970779231A5047686585 @default.
• W1970779231 hasConcept C126322002 @default.
• W1970779231 hasConcept C143998085 @default.
• W1970779231 hasConcept C156957248 @default.
• W1970779231 hasConcept C207103383 @default.
• W1970779231 hasConcept C2776256026 @default.
• W1970779231 hasConcept C2776694085 @default.
• W1970779231 hasConcept C2778019345 @default.
• W1970779231 hasConcept C2778695046 @default.
• W1970779231 hasConcept C2780333294 @default.
• W1970779231 hasConcept C44249647 @default.
• W1970779231 hasConcept C71924100 @default.
• W1970779231 hasConceptScore W1970779231C126322002 @default.
• W1970779231 hasConceptScore W1970779231C143998085 @default.
• W1970779231 hasConceptScore W1970779231C156957248 @default.
• W1970779231 hasConceptScore W1970779231C207103383 @default.
• W1970779231 hasConceptScore W1970779231C2776256026 @default.
• W1970779231 hasConceptScore W1970779231C2776694085 @default.
• W1970779231 hasConceptScore W1970779231C2778019345 @default.
• W1970779231 hasConceptScore W1970779231C2778695046 @default.
• W1970779231 hasConceptScore W1970779231C2780333294 @default.
• W1970779231 hasConceptScore W1970779231C44249647 @default.
• W1970779231 hasConceptScore W1970779231C71924100 @default.
• W1970779231 hasIssue "1" @default.
• W1970779231 hasLocation W19707792311 @default.
• W1970779231 hasLocation W19707792312 @default.
• W1970779231 hasOpenAccess W1970779231 @default.
• W1970779231 hasPrimaryLocation W19707792311 @default.
• W1970779231 hasRelatedWork W1943617196 @default.
• W1970779231 hasRelatedWork W2063019936 @default.
• W1970779231 hasRelatedWork W2064447907 @default.
• W1970779231 hasRelatedWork W2121015214 @default.
• W1970779231 hasRelatedWork W2135481547 @default.
• W1970779231 hasRelatedWork W2329364306 @default.
• W1970779231 hasRelatedWork W2793590385 @default.
• W1970779231 hasRelatedWork W2804529914 @default.
• W1970779231 hasRelatedWork W3038392370 @default.

• next